Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 311 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Unresectable Melanoma Clear all
Recruiting Phase 2 Interventional

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

NCT07237100
View directory record Official record
Conditions
Advanced Unresectable Melanoma, Metastatic Melanoma
Interventions
Mirdametinib
Drug
Lead sponsor
Kevin Kim, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

NCT01551693
View directory record Official record
Conditions
Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

NCT07288203
View directory record Official record
Conditions
Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma
Interventions
Lifileucel
Biological
Lead sponsor
Iovance Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography, Multigated Acquisition Scan, Biopsy, Biospecimen Collection, Computed Tomography, Positron Emission Tomography
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Results available

Melanoma Checkpoint and Gut Microbiome Alteration With Microbiome Intervention

NCT03817125
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Placebo for antibiotic, Vancomycin pretreatment, Nivolumab, Matching Placebo for SER-401, SER-401
Drug
Lead sponsor
Parker Institute for Cancer Immunotherapy
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Los Angeles, California • Boston, Massachusetts • New Brunswick, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 1 Interventional

Safety Study of MGD009 in B7-H3-expressing Tumors

NCT02628535
View directory record Official record
Conditions
Mesothelioma, Bladder Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non Small Cell Lung Cancer, Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Thyroid Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Colon Cancer, Soft Tissue Sarcoma
Interventions
MGD009
Biological
Lead sponsor
MacroGenics
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
14
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Phase 2 Interventional

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

NCT05136196
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
223
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 174 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Not listed Phase 2 Interventional

Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma

NCT03190824
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage Iv
Interventions
OBP-301
Drug
Lead sponsor
Syneos Health
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

Thalidomide and Docetaxel in Treating Patients With Advanced Cancer

NCT00049296
View directory record Official record
Conditions
Cancer
Interventions
docetaxel, thalidomide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2010 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma

NCT00942162
View directory record Official record
Conditions
Melanoma
Interventions
Immunotherapeutic GSK2132231A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
15
States / cities
Los Angeles, California • Orange, California • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Jul 20, 2026, 6:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Beta-only IL-2 ImmunoTherapY Study

NCT05086692
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer

NCT01673737
View directory record Official record
Conditions
Neoplasm Malignant
Interventions
SAR260301, Vemurafenib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 1 Interventional Results available

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

NCT01810016
View directory record Official record
Conditions
Unresectable or Metastatic Melanoma
Interventions
Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide, NY-ESO-1 OLP4 Vaccine with Poly-ICLC
Biological
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
New York, New York • Pittsburgh, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 1 Interventional

Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma

NCT01611675
View directory record Official record
Conditions
Melanoma
Interventions
Vemurafenib, Leflunomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

NCT00387751
View directory record Official record
Conditions
Recurrent Melanoma, Stage III Skin Melanoma, Stage IV Skin Melanoma
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

NCT03149029
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Pembrolizumab, Dabrafenib, Trametinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

NCT01515189
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
11
States / cities
Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 3 Interventional Results available

Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma

NCT01597908
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Vemurafenib, Trametinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
704 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Gilbert, Arizona • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

NCT04417621
View directory record Official record
Conditions
Melanoma
Interventions
LXH254, LTT462, Trametinib, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 120 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
12
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Early Phase 1 Interventional

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

NCT02652455
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
Nivolumab, Surgery to Remove Tumor for Growth of TIL, CD137, Cyclophosphamide, Fludarabine, TIL Infusion, Interleukin-2
Drug · Procedure · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Jul 20, 2026, 6:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 1 Interventional

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

NCT04551352
View directory record Official record
Conditions
Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma
Interventions
RO7293583, Tocilizumab, Obinutuzumab, Adalimumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2022 · Synced Jul 20, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E

NCT01586195
View directory record Official record
Conditions
Malignant Melanoma
Interventions
Vemurafenib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
16 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
15
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 24, 2017 · Synced Jul 20, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma

NCT00072345
View directory record Official record
Conditions
Intraocular Melanoma, Melanoma (Skin)
Interventions
lomustine, temozolomide, thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Jul 20, 2026, 6:42 PM EDT